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ObesityAbstract Resistin is an adipocyte secreted hormone, to investigate the relationship between levels
of serum resistin and C-reactive protein (as an inﬂammatory marker) together with insulin resis-
tance and the presence of retinopathy in type 2 diabetes mellitus in Egyptian subjects, we measured
fasting serum resistin and CRP levels in thirty obese diabetic subjects (with different grades of ret-
inopathy: ten diabetic patients without retinopathy, ten diabetic patients with non-proliferative ret-
inopathy and ten diabetic patients with proliferative retinopathy) and compared them with the
results of ten obese non diabetic subjects and ten non obese healthy volunteers. Insulin resistance
was assessed using the homeostasis model assessment for insulin resistance (HOMA-IR). All sub-
jects were investigated to analyze the change in their total cholesterol, HDL-C, LDL-C, and triglyc-
erides levels. Fasting glucose and insulin resistance were signiﬁcantly higher (P< 0.05) in diabetic
compared with non diabetic subjects. Fasting Serum resistin and CRP were highly signiﬁcantly dif-
ferent among the groups of study (P< 0.001). Fasting serum resistin concentration showed highly
signiﬁcant positive correlation with CRP, BMI (body mass index), serum insulin, HOMA-I.R, and
FBS (fasting blood sugar) and it was signiﬁcantly positively correlated with waist, hip circumfer-
ences and triglycerides levels, while it was signiﬁcantly negatively correlated with HDL-C. Serum
resistin was associated with the presence of retinopathy in T2DM.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Resistin is a member of a secretory protein family, known as
resistin-like molecules (RELMs) (Steppan and Lazar, 2004).
It was originally named for its resistance to insulin (Steppan
et al., 2001). Resistin is expressed in white adipose tissue with
the highest levels in female gonadal adipose tissue (Steppan
and Lazar, 2002), besides adipose tissue, human resistin is also
expressed in other varieties of human tissues. Real-time PCR
showed that human resistin was expressed at the highest level
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Human resistin mRNA has also been detected in the nonfat
cells of adipose depots (Fain et al., 2003).
Resistin was identiﬁed as a possible link between obesity
and insulin resistance (Chen et al., 2002). Insulin resistance is
a fundamental aspect of the etiology of type 2 diabetes and
is also linked to a wide array of other pathophysiologic sequels
including hypertension, hyperlipidemia, atherosclerosis and
polycystic ovarian disease (Reaven, 1995). A speciﬁc complica-
tion of diabetes, microangiopathy, includes retinopathy,
nephropathy, and neuropathy (Mabley and Soriano, 2005).
The development or progression of diabetic microangiopathy
could be affected by serum resistin (Osawa et al., 2007a).
Several recent human studies have supported the concept of
inﬂammatory cytokine mediation of resistin (Mattevi et al.,
2004), however, resistin associations with inﬂammatory mark-
ers appear to be independent of BMI, suggesting that resistin
may have a direct proinﬂammatory role or mediate its effects
via yet to be discovered obesity-independent mecha-
nisms(Greeshma et al., 2004), C-reactive protein (CRP) is an
inﬂammatory biomarker (Sun et al., 2005), involved in endo-
thelial dysfunction and atherogenesis (Torzewski et al.,
2000). Inﬂammation as measured by serum C-reactive protein
has been shown to be increased in people with diabetes who
have macro vascular complications (Zhao et al., 2011), and
microangiopathy (Matsumoto et al., 2002).
In view of this, we investigated the correlation between ser-
um resistin level and insulin resistance in obesity and type 2
diabetes mellitus together with serum resistin and CRP levels
in relation to the presence of diabetic retinopathy in ﬁfty Egyp-
tian subjects.
2. Materials and methods
The study was conducted on ﬁfty unrelated Egyptian subjects
divided into three groups: group1 (control group) consists of
ten non obese non diabetic healthy volunteers, group 2 consists
of ten obese, non diabetic subjects and group 3 consists of
thirty obese, diabetic subjects divided into 3 subgroups:
 Group 3a: includes ten patients without diabetic
retinopathy.
 Group 3b: includes ten patients with non proliferative dia-
betic retinopathy.
 Group 3c: includes ten patients with proliferative diabetic
retinopathy.
Diabetes mellitus was diagnosed based on the American
Diabetes Association criteria, as reported in 1998. All subjects
were informed of the purpose of the study and their consent
was obtained. Physical data for each subject, including weight,
height, waist and hip circumferences were recorded. Non dia-
betic volunteers were judged to be in good health according
to their medical history and their fasting blood glucose level
(<100 mg/dL).The subjects in group 3 were subjected to fun-
dus examination for detection of the presence of retinopathy
and laboratory investigations including, fasting blood glucose
level by colorimetric method and fasting serum insulin level
(Pal et al., 2008). Insulin resistance was measured using the
homeostasis model assessment of insulin resistance (HOMA-
IR), a reliable marker for insulin resistance, was calculatedas fasting insulin · glucose level/22.5 (Katz et al., 2000). Serum
resistin was measured using a human resistin ELISA kit (Bend-
er Medsystems, Inc) (Greeshma et al., 2004). Subjects also
were assayed for C-reactive protein (Ridker et al., 2002), and
Lipid proﬁle (Al-Omar et al.,2010) & (Mehrotra et al.,2009).2.1. Statistical analysis
The collected data were tabulated and analyzed using SPSS
version 16 software. Categorical data were presented as num-
ber and percentages, Chi square test (X2) was used as a test
of signiﬁcance while quantitative data were expressed as mean
and standard deviation. Comparison of variables among
groups of the study was made by one way analysis of variance
(ANOVA). The Student ‘‘t’’ test was used to compare the
means for pairs of groups. Correlation between serum resistin
and other parameters of the subjects was determined by Pear-
son’s Product correlation coefﬁcient (r) to test the strength of
association between serum resistin and other variables. Bonfer-
roni’s correction was also applied to analyses. Differences were
considered statistically signiﬁcant at P< 0.05 and highly sig-
niﬁcant at P< 0.01, to examine the relationship between ser-
um resistin and retinopathy, simple regression analysis
involving retinopathy stage as a dependent variable and serum
resistin as an independent variable was performed. The recei-
ver operating characteristic (ROC) curve was used to evaluate
the performance of fasting serum resistin level as an indicator
of developing retinopathy in diabetic subjects, speciﬁcity and
sensitivity of different cut off values were estimated. An area
under the ROC curve of 1.0 indicates perfect discrimination,
whereas an area of 0.5 indicates that the test discriminates
no better than chance (Zweig and Campbell, 1993).3. Results
Fasting glucose and insulin resistance, as assessed using the
homeostasis model of insulin resistance ratio (HOMA-IR),
were similar in non obese and obese subjects, but signiﬁcantly
higher (P< 0.05) in diabetic compared with non diabetic
subjects.
Fasting serum resistin was highly signiﬁcantly (P< 0.01)
different among the ﬁve groups (Table 1), mean serum resistin
concentration increased in ascending manner in the ﬁve
groups, showing the highest level in subjects with proliferative
diabetic retinopathy. Bonferroni adjustment revealed that
there was a signiﬁcant difference between diabetic non retinop-
athy subjects and subjects with proliferative diabetic
retinopathy.
The serum C-reactive protein levels showed a high signiﬁ-
cant difference between non diabetic and diabetic groups
(P< 0.01), the comparison between diabetic non retinopathy
group (DNR), and non-proliferative diabetic retinopathy
group (NPDR) showed a high signiﬁcant difference too
(P< 0.01), so it appears that CRP concentrations were signif-
icantly associated with the presence of retinopathy.
Fasting serum resistin concentrations were not correlated
with those of LDL-C, whereas there was a highly signiﬁcant
positive correlation between serum resistin concentrations
and triglycerides, CRP, serum insulin and FBS concentrations,
the same results were seen with BMI and HOMA-R. Serum
Table 1 Fasting serum resistin and other variables in groups of the study (values are mean + SD).
Variables Group1 Group 2 Group 3a Group 3b Group 3c F P
X± S.D X± S.D X± S.D X± S.D X± S.D
n= 10 n= 10 n= 10 n= 10 n= 10
Total cholesterol (mg/dl) 177.3 ± 13.8 192 ± 7.6 260 ± 49.6 221.2 ± 35.9 208.3 ± 30.7 10.144 <0.05*
HDL-C (mg/dl) 42.5 ± 7.78 27.3 ± 2.685 27.2 ± 4.07 27 ± 3.605 26.5 ± 4.08 21.126 <0.01*
LDL-C (mg/dl) 108.4 ± 12.22 112.7 ± 5.46 165.5 ± 40.4 130 ± 33.193 119 ± 30.1 6.896 NS
Triglycerides (mg/dl) 132 ± 25.83 259.8 ± 27.8 336.3 ± 42.2 320.3 ± 39.11 314.9 ± 49.2 48.526 <0.01
(HOMA –IR) (mg/dl) 1.37 ± 0.23 2.65 ± 0.53 8.46 ± 3.81 12.77 ± 6.31 17.72 ± 3.91 33.640 <0.01
Resistin (ng/ml) 11.79 ± 2.2 18.82 ± 3.2 20.96 ± 3.19 21.65 ± 3.21 25.55 ± 5.96 18.102 <0.01
BMI (kg/m2) 21.8 ± 1.6 33.1 ± 1.4 36.00 ± 4.2 36.50 ± 6.5 33.9 ± 2.4 25.79 <0.01
CRP (mg/dl) 3.5 ± 0.45 4.2 ± 0.8 8.9 ± 1.9 12.3 ± 1.2 13.7 ± 1.7 121.16 <0.05
P< 0.05 signiﬁcant and P< 0.01 highly signiﬁcant. NS : non-signiﬁcant.
Table 2 Pearson’s product correlation coefﬁcient (r) of
resistin with anthropometric and metabolic parameters in
groups of the study.
Variables r P
Age (years) 0.4652 <0.01
BMI(kg/m2) 0.5051 <0.01
Hip (cm) 0.3889 <0.05
Waist (cm) 0.3863 <0.05
FBS (mmol/L) 0.5086 <0.01
HOMA-R (lU/mL-mmol/L) 0.5908 <0.01
Insulin(lU/Ml) 0.6595 <0.01
Total cholesterol 0.2358 <0.01
HDL cholesterol 0.3958 <0.05
LDL cholesterol 0.0579 NS
Triglycerides 0.6614 <0.01
CRP 0.6678 <0.01
P< 0.05 signiﬁcant, P< 0.01 highly signiﬁcant. NS: non-
signiﬁcant.
274 N. Azab et al.resistin is signiﬁcantly positively correlated with waist and hip
circumferences while it is signiﬁcantly negatively correlated
with HDL-C (Table 2).
Serum resistin was also signiﬁcantly correlated with the
stage of retinopathy, simple regression analysis was performed
involving retinopathy stage as a dependent variable and serum
resistin as an independent variable (Table 3), (Fig. 1).
3.1. Fasting serum resistin cut off points for diabetic retinopathy
ROC curve analysis was performed in order to establish a
threshold serum resistin concentration for the existence of dia-
betic retinopathy. However, there was no statistically signiﬁ-Table 3 Serum resistin was correlated with retinopathy stage.
Un standardized reg
coeﬃcient
Retinopathy stage (dependent
variable)
0.1541
For simple regression analysis, each of retinopathy stage (no retinopathy
dependent variable, and serum resistin (ng/ml)as an independent variable.
methods.cant cut-off value of serum resistin for the presence of
retinopathy, nevertheless results revealed that resistin concen-
tration is signiﬁcantly positively correlated with the retinopa-
thy stage (Fig. 1).
4. Discussion
Our study reports the resistin levels in non-obese, obese
healthy and obese diabetic Egyptian subjects. Over the past
few years, several studies in humans have examined the rela-
tionship between circulating resistin levels and obesity or dia-
betes. The results of these studies have been difﬁcult to
interpret and contradictory as a consequence of differences
in ethnicity and clinical background of the subjects investi-
gated, or the target epitopes used in the resistin assays.
In the present study, our results showed that circulating lev-
els of resistin were signiﬁcantly elevated in obese compared to
non-obese subjects and obese diabetic subjects had the highest
serum resistin levels. This agrees with Al-Harithy & Al-Gha-
mdi study in 2005 who reported higher serum resistin levels
in healthy obese compared to non-obese individuals and high-
est resistin levels in obese diabetic subjects, also Mcternan
et al. (2002) reported higher serum resistin levels in healthy ob-
ese compared to non-obese individuals. The results of Youn
et al. (2004) and Fujinami et al. (2004) also agree with our re-
sults as they revealed that serum resistin levels were signiﬁ-
cantly higher in diabetic patients compared to control subjects.
On the other side some studies reported that the serum res-
istin levels were not correlated with body mass index or blood
glucose (Takeishi et al., 2007), also Heilbronn et al. (2004)
found that there was no signiﬁcant difference of resistin con-
centrations among non-obese, obese and obese diabetic
subjects.ression Standardized regression
coeﬃcient
Standard
error
P
0.1238 0.03 0.0319
= 0, nonproliferative = 1, and proliferative = 2), was involved as a
The deﬁnition of the stages for retinopathy described in Materials and
Figure 1 simple regression analysis of the retinopathy stage
(no = 0, non-proliferative = 1 and proliferative = 2) as a depen-
dent variable and resistin concentration (ng/ml) (values are
mean + SD) as an independent variable reveals that resistin
concentration is signiﬁcantly positively correlated with the reti-
nopathy stage.
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obesity), have been used as indicators or measures of the
health of a person, and the risk of developing serious health
conditions. Research shows that people with ‘‘apple-shaped’’
bodies (with more weight around the waist) face more health
risks than those with ‘‘pear-shaped’’ bodies who carry more
weight around the hip (Reilly et al., 2002).
The current study showed that the waist circumferences ra-
tio was signiﬁcantly higher in the diabetic groups than in non-
diabetic groups. This is in accordance with Reilly et al. (2002).
Also the waist circumferences were signiﬁcantly higher in ob-
ese group than in non-obese group, this means that these obese
patients may be prone to the development of health problems
including diabetes.
Regarding the relationship between insulin level, insulin
resistance and resistin, we reported that resistin levels were sig-
niﬁcantly positively correlated with insulin levels and insulin
resistance as assessed by HOMA-IR. Thus our data add to
the growing body of evidence indicating that in humans there
is a direct relationship between circulating levels of resistin and
insulin, and several studies show similar results (Al-Harithy
and Al-Ghamdi, 2005; Zhang et al., 1994). Accordingly, sev-
eral studies have identiﬁed positive correlations between resi-
stin levels and insulin resistance in vivo (Silha et al., 2003)
and in vitro (Smith et al., 2003). Conversely, other studies re-
ported no associations between serum resistin levels and mark-
ers of insulin resistance in Type 2 Diabetes Mellitus patients or
insulin-resistant patients. Moreover, serum and plasma resistin
levels were either reduced or increased in Type 2 Diabetes Mel-
litus patients with no signiﬁcant correlation with HOMA-IR.
Consequently, these studies suggest that resistin is unlikely to
play a critical endocrine role in insulin resistance or energy
homoeostasis in humans (e.g. Urbanek et al., 2003). Neverthe-
less, a paracrine or autocrine manner of resistin to moderately
affect metabolism cannot be ruled out (Kusminski et al.,2005).
Insulin is known to upregulate lipoprotein lipase, a critical
factor producing HDL cholesterol through lipoprotein metab-olism. Therefore, insulin resistance caused by elevated plasma
resistin could result in reduced serum HDL cholesterol.
We showed that serum resistin was inversely associated with
serum HDL cholesterol. This was in agreement with authors
suggesting that resistin was associated with lowHDL cholesterol
(e.g. Chen et al., 2005), also this was in agreement with Sato et al.
(2005), who stated that over expression of resistin in the liver
using adenovirus in mice showed enhanced insulin resistance
and low serum HDL cholesterol (Osawa et al., 2007b).
Others found no signiﬁcant correlation between resistin and
HDL-cholesterol e.g. (Mohammadzadeh et al., 2008).
A speciﬁc complication of diabetes, microangiopathy, in-
cludes retinopathy, nephropathy, and neuropathy. Hypergly-
cemia increases polyol pathway ﬂux, protein kinase C (PKC)
activity, and the production of advanced glycation end prod-
ucts (AGE), and reactive oxygen species (ROS) (Mabley and
Soriano, 2005). So the development or progression of diabetic
microangiopathy could be affected by serum resistin (Osawa
et al., 2007a).
Within the diabetic group serum resistin was highly signif-
icantly increased in individuals with proliferative retinopathy
and it appeared that serum resistin was associated with reti-
nopathy stage; this is consistent with the study of Osawa
et al. (Osawa et al., 2007a), Sun Fundun et al. (Fudun et al.,
2004) and Wang Jin et al. (Jin et al., 2005), and inconsistent
with (Schafﬂer et al., 2004) who stated that there was no cor-
relation between resistin levels and occurrence of diabetic ret-
inopathy or nephropathy.
Resistin appears to be involved in inﬂammatory pathways,
activating vascular endothelial cells, leading to increased
expression of adhesion molecules, and stimulating smooth
muscle cell proliferation (Krec¸ki et al., 2011). Furthermore,
some clinical and epidemiological studies revealed positive cor-
relations between plasma resistin levels and pro-inﬂammatory
cytokines (Kawamura et al., 2010).
We reported serum CRP levels (as an inﬂammatory mar-
ker) in the groups of the study, our results showed that there
was a signiﬁcant difference of CRP levels in the diabetic pa-
tients, as compared to non-diabetic groups, also a signiﬁcant
difference was seen in patients with retinopathy as compared
to diabetic patients without any grade of retinopathy.
This was in agreement with Zhao et al. (2011) who stated
that inﬂammation as measured by serum C-reactive protein
has been shown to be increased in people with diabetes and
Matsumoto et al. (2002) who concluded that CRP increased
in diabetic patients with microangiopathy, however, the asso-
ciations of CRP with the microvascular complications of dia-
betes, or diabetic retinopathy in particular, have been
inconsistent from the few studies that examined this associa-
tion. In the European diabetes study (Schram et al., 2005).
CRP was found to be positively associated with DR severity,
but when BMI was added to the model, the association was
no longer signiﬁcant. Similarly, in a longitudinal study of pa-
tients with type 2 diabetes, Spijkerman et al.(2007) reported
that CRP was cross-sectionally associated with baseline preva-
lence of diabetic retinopathy, but this association was not inde-
pendent of HbA1c levels and BMI and there were also no
associations between CRP levels and DR progression. Other
studies, however, reported no association between CRP levels
and diabetic retinopathy (Van Hecke et al., 2005) and (Nguyen
et al., 2009). For example, prospective data from the WESDR
(Wisconsin Epidemiologic Study of Diabetic Retinopathy)
276 N. Azab et al.(Klein et al., 2009) found that CRP levels were not associated
with DR incidence or progression.
5. Conclusion
Resistin is signiﬁcantly positively correlated with CRP levels,
being an inﬂammatory marker, supporting the inﬂammatory
role of resistin, which may interpret association with the pres-
ence of retinopathy.
The association of resistin with the severity of diabetic ret-
inopathy may open up future projects on the early detection
and prevention of the condition. However, as we were unable
to establish a threshold concentration for the development of
retinopathy, we cannot propose the measurement of serum res-
istin concentration as a candidate test for establishing the risk
of developing diabetic retinopathy.
In summary, we report here that serum resistin was higher
in diabetic than in healthy subjects, furthermore it is correlated
with diabetes linked risk factors, obesity and insulin resistance.
It is also higher in patients with diabetic retinopathy than in
those without it, and is involved in the generation of diabetes
and diabetic retinopathy. Future prospective studies with
greater numbers of patient are recommended to establish a di-
rect relationship between serum resistin concentrations and the
severity of microangiopathy.
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